Metronidazole 0.75% vaginal gel — Membership Pricing
Metronidazole 0.75% vaginal gel is not confirmed for no-additional-cost pricing. Membership pricing may be available; confirm the price with the dispensing pharmacy.
Metronidazole 0.75% vaginal gel Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | Membership pricing may be available |
| Typical Retail | $183.00 |
Membership pricing may be available; confirm the price with the dispensing pharmacy.
About Metronidazole 0.75% vaginal gel
Metronidazole 0.75% vaginal gel is a prescription medication. Ask your doctor if Metronidazole 0.75% vaginal gel is right for you.
Other strengths and forms of Metronidazole
Conditions Treated with Metronidazole 0.75% vaginal gel
How to Check Metronidazole 0.75% vaginal gel Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available membership pricing
Metronidazole 0.75% vaginal gel at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
What Metronidazole 0.75% vaginal gel is approved for (FDA label)
VANDAZOLE ® is indicated in the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, Corynebacterium vaginitis, or anaerobic vaginosis) in post-menarchal females. VANDAZOLE is a nitroimidazole antimicrobial indicated for the treatment of bacterial vaginosis in post-menarchal females. ( 1 )
Source: Read the full FDA label on DailyMed. Label effective date: December 2, 2025.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Dosage forms and strengths for Metronidazole 0.75% vaginal gel (FDA label)
Gel, 0.75%. VANDAZOLE is a clear, colorless to yellow gel in a 70 g tube, supplied with 5 vaginal applicators. Each applicator delivers approximately 5 g of gel containing 37.5 mg of metronidazole, USP. Vaginal gel 0.75% in a 70 g tube with 5 vaginal applicators (each applicator delivers approximately 5 g of gel containing 37.5 mg of metronidazole) ( 3 ).
Source: FDA prescribing information (DailyMed). Set ID: 27d71471-8f89-4a1e-8c55-020a58961454. SPL document ID: 44ff0133-9823-f57e-e063-6294a90a5c73. Label effective date: December 2, 2025. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Metronidazole 0.75% vaginal gel (FDA label)
Adverse reactions occurring in ≥ 1% of patients are: fungal infection, headache, pruritus, abdominal pain, nausea, dysmenorrhea, pharyngitis, rash, infection, diarrhea, breast pain, and metrorrhagia. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Teva Pharmaceuticals USA, Inc. at 1-888-838-2872 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The data described below reflect exposure to VANDAZOLE compared to another formulation of vaginal metronidazole in 220 women in a single trial.
Source: FDA prescribing information (DailyMed). Set ID: 27d71471-8f89-4a1e-8c55-020a58961454. SPL document ID: 44ff0133-9823-f57e-e063-6294a90a5c73. Label effective date: December 2, 2025. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Metronidazole 0.75% vaginal gel (FDA label)
History of hypersensitivity to metronidazole, other nitroimidazole derivatives or parabens ( 4 ) Disulfiram: Psychotic reactions have been reported with disulfiram and oral metronidazole; do not administer concurrently with or within the last 2 weeks of disulfiram ( 4.2 , 7.1 ). Alcohol: Disulfiram-like reactions to alcohol have been reported with oral metronidazole; do not consume alcohol during and for at least three days following treatment ( 4.3 , 7.2 ) 4.1 Hypersensitivity The use of VANDAZOLE is contraindicated in patients with a history of hypersensitivity to metronidazole, other nitroimidazole derivatives, or parabens. Reported reactions include urticaria; erythematous rash; Stevens-Johnson Syndrome, toxic epidermal necrolysis, flushing; nasal congestion; dryness of the mouth, vagina, or vulva; fever; pruritus; fleeting joint pains [see Adverse Reactions ( 6.2 )] . 4.2 Psychotic Reaction with Disulfiram Use of oral metronidazole is associated with psychotic reactions in alcoholic patients who were using disulfiram concurrently.
Source: FDA prescribing information (DailyMed). Set ID: 27d71471-8f89-4a1e-8c55-020a58961454. SPL document ID: 44ff0133-9823-f57e-e063-6294a90a5c73. Label effective date: December 2, 2025. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Warnings and precautions for Metronidazole 0.75% vaginal gel (FDA label)
Central and Peripheral Nervous System Effects: Convulsive seizures and peripheral neuropathy have been reported in patients treated with oral or intravenous metronidazole; discontinue if abnormal neurologic signs develop. ( 5.1 ) Carcinogenicity in Animals: Metronidazole has been shown to be carcinogenic in mice and rats. ( 5.2 , 13.1 ) Interference with laboratory tests: Metronidazole may interfere with certain serum chemistry laboratory values ( 5.3 ) 5.1 Central and Peripheral Nervous System Effects Use of oral or intravenous metronidazole is associated with convulsive seizures, encephalopathy, aseptic meningitis, optic and peripheral neuropathy, the latter characterized mainly by numbness or paresthesia of an extremity [see Adverse Reactions ( 6.2 )] . VANDAZOLE should be administered with caution to patients with central nervous system diseases.
Source: FDA prescribing information (DailyMed). Set ID: 27d71471-8f89-4a1e-8c55-020a58961454. SPL document ID: 44ff0133-9823-f57e-e063-6294a90a5c73. Label effective date: December 2, 2025. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Drug interactions for Metronidazole 0.75% vaginal gel (FDA label)
The intravaginal administration of a single 5 gram dose of VANDAZOLE results in relatively lower mean systemic exposure to metronidazole that is approximately 2% to 5% of that achieved following a 500 mg oral dose of metronidazole [see Clinical Pharmacology ( 12.3 )] . The following drug interactions were reported for oral metronidazole. Warfarin and other coumarin anticoagulants: Prolonged anticoagulant effects reported with oral metronidazole; monitor INR and prothrombin time. ( 7.3 ) Lithium: Elevated lithium concentrations reported with oral metronidazole; monitor serum concentrations of lithium. ( 7.4 ) 7.1 Disulfiram Use of oral metronidazole has been associated with psychotic reactions in alcoholic patients who are using disulfiram concurrently.
Source: FDA prescribing information (DailyMed). Set ID: 27d71471-8f89-4a1e-8c55-020a58961454. SPL document ID: 44ff0133-9823-f57e-e063-6294a90a5c73. Label effective date: December 2, 2025. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.